VolitionRX Ltd VNRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
VolitionRx Announces Pricing of $4.6 Million Public Offering
-
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
-
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
-
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
-
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
-
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
-
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
-
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
Trading Information
- Previous Close Price
- $1.79
- Day Range
- $1.39–1.55
- 52-Week Range
- $1.39–18.78
- Bid/Ask
- $1.38 / $1.39
- Shares Outstanding
- 8.63M
- Market Cap
- $12.38M
- Volume/Avg
- 298,848 / 631,879
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://www.volition.com
Valuation
|
Metric
|
VNRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4.25 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VNRX
|
|---|---|
Quick Ratio | 0.25 |
Current Ratio | 0.33 |
Interest Coverage | −7.33 |
Quick Ratio
VNRX
Profitability
|
Metric
|
VNRX
|
|---|---|
Return on Assets (Normalized) | −284.07% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
VNRX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Vdxpclh | Rgtbtr | $159B | |||
| Stryker Corp
SYK
| Hvxccvdvp | Bkr | $117B | |||
| Medtronic PLC
MDT
| Zcdfvxym | Jtkgrs | $105B | |||
| Boston Scientific Corp
BSX
| Mskfgjc | Thvxh | $72B | |||
| Edwards Lifesciences Corp
EW
| Pcjdnwgc | Jspjs | $49B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| Tktgmss | Vqgcs | $29B | |||
| DexCom Inc
DXCM
| Vcntfsjg | Kjccs | $28B | |||
| Koninklijke Philips NV ADR
PHG
| Drtt | Rnmt | $26B | |||
| Steris PLC
STE
| Ccksrhylk | Zxjjh | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| Fhqwlrmyp | Fjg | $17B |
United States